PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

News & events

Press release
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

Read more
News
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

As of December 31, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling €10.5 million (approximately $11.6 million).

Read more
Press release
PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

Conference call and webcast (English) on Wednesday, November 15, 2023at 8:30am ET / 2:30pm CET

Read more
News
PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

Read more
Press release
PHAXIAM announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps has initiated coverage of its shares

TP ICAP Midcap began covering the stock with a “Buy” recommendation and valued the Company at €8.5 per share

Read more
Press release
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains 

Read more
Press release
PHAXIAM Receives Compliance Notice from Nasdaq

Read more
Press release
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration

Read more
Press release
PHAXIAM Provides Business and Financial Update – For the First Half of 2023

Read more
Press release
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target

Read more
Press release
PHAXIAM Therapeutics announces the completion of its reverse share split

Read more
Press release
PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences

Read more

Contact
our team

Journalist, investor, healthcare professional, partner or candidate... if you have any questions about PHAXIAM, please do not hesitate to contact our teams.

Contact us